Michael Makris on Immediate Suspension of Use of Plasma Derived FIX Concentrates in Punjab
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, Editor-in-Chief of RPTH Journal, shared on LinkedIn:
”This is worrying.
The Tribune newspaper in India is reporting that authorities have asked for the immediate suspension of use (and quarantining) of six batches of plasma derived factor IX concentrate for use in haemophilia B.
The products are made by a company called ICHOR Biologics, a company I have not heard of before.
The article is missing two critical pieces of information:
a) What is the adverse event that led to the suspension of this product
b) How many patients are affected. Only the total number of patients in the region are given.
I really hope this is not new transmission of a viral infection in persons with haemophilia.
The story may be a local one in Punjab in India, but the international world of haemophilia will be following this story.”
Read The Tribune article here.
Stay updated on the emerging with Hemostasis Today.
-
Dec 16, 2025, 14:03Francesco Lo Monaco on Rethinking Blood Pressure: The Major Problem with How We Understand It
-
Dec 16, 2025, 14:03Marilena Vrana Urges EU Policymakers to “Keep Patients at the Centre” of Critical Medicines Act
-
Dec 16, 2025, 14:02Even Distribution of Protective Hemoglobin Prevents Sickle Cell Symptoms
-
Dec 16, 2025, 13:58AHA Awards Shubham Misra Postdoc Grant for LVO Stroke Biomarker Research
-
Dec 16, 2025, 13:00ScholarGPS Ranks Emmanuel J. Favaloro No. 1 in the World for Hemostasis
-
Dec 16, 2025, 11:30Kingsley Wheaton: Sweden is on the Brink of Becoming the World’s 1st Smoke-Free Country
-
Dec 16, 2025, 11:03Matías J Alet on CABOS Project with The Support of WSO
-
Dec 16, 2025, 00:32New on EHCucate: Read about the “History of Replacement Factor Therapies” and More
-
Dec 15, 2025, 23:36In a Time of Crisis: Dr. Amanda Rischbieth on Blood Donation, Solidarity, and Saving Lives